Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Purchased by Pathstone Holdings LLC

Pathstone Holdings LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 11.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,249 shares of the biopharmaceutical company’s stock after purchasing an additional 629 shares during the period. Pathstone Holdings LLC’s holdings in Alnylam Pharmaceuticals were worth $1,719,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in the business. Huntington National Bank lifted its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 45 shares during the period. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $26,000. Washington Trust Advisors Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $42,000. Finally, Friedenthal Financial acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $51,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Tolga Tanguler sold 1,469 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CMO Pushkal Garg sold 1,682 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the completion of the sale, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,370 shares of company stock valued at $2,100,703 over the last ninety days. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

ALNY has been the subject of several analyst reports. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $198.00 to $370.00 in a research note on Friday, August 16th. Piper Sandler reissued an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $253.74 on Thursday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a market cap of $32.73 billion, a PE ratio of -96.85 and a beta of 0.39. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a 50 day moving average price of $272.32 and a 200 day moving average price of $240.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue was down 33.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.15 earnings per share. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.